Program
BI 3802876
A development code.
In Boehringer Ingelheim's pipeline, Anti-fibrotic agent
. Its studies are mostly in Liver Cirrhosis, led by Boehringer Ingelheim.
Furthest: phase 2, since Jan 7, 20262 company-led studies, 1 open or runningNext primary completion: Aug 5, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 21 open or running | phase 2since Jan 7, 2026 | Oct 6, 2023 | Aug 5, 2027phase 2 · NCT07325526 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 3802876
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2023First study: phase 1 study in HealthyFirst studyNCT06081530 · 59 enrolled · Belgium
- Jan 7, 2026Phase 2 study in Liver CirrhosisPhase 2 reachedNCT07325526 · 30 planned · United States, Canada
Ahead
- Aug 5, 2027Primary completion: phase 2 study in Liver CirrhosisNCT07325526
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Anti-fibrotic agent”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07325526Liver Cirrhosis · United States, Canada | 2 | Recruiting | Aug 5, 2027 | 30 |
| NCT06081530Healthy · Belgium | 1 | Completed | Mar 20, 2025 | 59 |
How it is read
Names in the registry
- “BI 3802876”, 2 entries
Codes read as this program: BI3802876.
Conditions, from the studies’ own filings
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.